These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 38191386)

  • 21. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
    Attia S; Guirguis M; Le LQ; Chhabra A
    Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner.
    Alewine G; Knight J; Ghantae A; Mamrega C; Attiah B; Coover RA; Fahrenholtz CD
    J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.
    Farschtschi S; Kluwe L; Park SJ; Oh SJ; Mah N; Mautner VF; Kurtz A
    Cancer Immunol Immunother; 2020 Jul; 69(7):1307-1313. PubMed ID: 32193699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant peripheral nerve sheath tumor: models, biology, and translation.
    Somatilaka BN; Sadek A; McKay RM; Le LQ
    Oncogene; 2022 Apr; 41(17):2405-2421. PubMed ID: 35393544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.
    Danielsen SA; Lind GE; Kolberg M; Høland M; Bjerkehagen B; Sundby Hall K; van den Berg E; Mertens F; Smeland S; Picci P; Lothe RA
    Neuro Oncol; 2015 Jan; 17(1):63-9. PubMed ID: 25038505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing T-cell dysfunction and exclusion signatures in malignant peripheral nerve sheath tumors reveals susceptibilities to immunotherapy.
    Bhandarkar AR; Bhandarkar S; Babovic-Vuksanovic D; Parney IF; Spinner RJ
    J Neurooncol; 2023 Sep; 164(3):693-699. PubMed ID: 37755632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synchronous cutaneous malignant peripheral nerve sheath tumor and jejunal gastrointestinal stromal tumor and submucosal angiomyolipoma in type 1 neurofibromatosis: A case report and literature review.
    Kim KJ; Kim MS; Hong R; Lim SC
    Medicine (Baltimore); 2023 Jan; 102(3):e32696. PubMed ID: 36701730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
    Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
    Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Jones J; Cain S; Pesic-Smith J; Choong PFM; Morokoff AP; Drummond KJ; Dabscheck G
    J Neurooncol; 2021 Sep; 154(3):265-274. PubMed ID: 34529228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case report of giant malignant schwannoma of the sciatic nerve associated with neurofibromatosis-1: A CARE-compliant article.
    Gokkus K; Saylik M; Birtay T; Sahin MS
    Medicine (Baltimore); 2023 Nov; 102(47):e36358. PubMed ID: 38013269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
    Upadhyaya M; Spurlock G; Majounie E; Griffiths S; Forrester N; Baser M; Huson SM; Gareth Evans D; Ferner R
    Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Kahn J; Gillespie A; Tsokos M; Ondos J; Dombi E; Camphausen K; Widemann BC; Kaushal A
    Front Oncol; 2014; 4():324. PubMed ID: 25452937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXM1, MEK, and CDK4/6: New Targets for Malignant Peripheral Nerve Sheath Tumor Therapy.
    Voigt E; Quelle DE
    Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of Survival Differences Between Cutaneous and Subcutaneous Malignant Peripheral Nerve Sheath Tumors.
    Kromer CM; Yacoub N; Xiong D; Knackstedt T
    Dermatol Surg; 2023 Apr; 49(4):322-329. PubMed ID: 36763849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of neurofibromatosis 1-associated malignant peripheral nerve sheath tumors: a systematic review.
    Tora MS; Xenos D; Texakalidis P; Boulis NM
    Neurosurg Rev; 2020 Aug; 43(4):1039-1046. PubMed ID: 31209658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.
    Bottillo I; Ahlquist T; Brekke H; Danielsen SA; van den Berg E; Mertens F; Lothe RA; Dallapiccola B
    J Pathol; 2009 Apr; 217(5):693-701. PubMed ID: 19142971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.